Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation

PURPOSE: To evaluate the outcomes of immune checkpoint inhibitor (ICI)-based treatments versus classical chemotherapy for metastatic non-small cell lung cancer (NSCLC) patients who develop epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance and to explore the population...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Yajie, Yang, Bin, Ouyang, Wen, Jie, Chen, Zhang, Wei, Chen, Gang, Zhang, Junhong, Yu, Jing, Xie, Conghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445807/
https://www.ncbi.nlm.nih.gov/pubmed/36081560
http://dx.doi.org/10.3389/fonc.2022.920047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445807/
https://www.ncbi.nlm.nih.gov/pubmed/36081560
http://dx.doi.org/10.3389/fonc.2022.920047

Ejemplares similares